Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
Samuel G. Ruchman, Prabhjot Singh, MD, PhD, and Anna Stapleton
What can American health systems developers learn from abroad? Leading programs draw on global lessons to build sustainable and effective care in the US.
AMA J Ethics. 2016;18(7):736-742. doi:
10.1001/journalofethics.2016.18.7.msoc1-1607.